FXYD6: a novel therapeutic target toward hepatocellular carcinoma
Protein & Cell
;
(12): 532-543, 2014.
Artigo
em Inglês
| WPRIM
| ID: wpr-757488
ABSTRACT
FXYD6, FXYD domain containing ion transport regulator 6, has been reported to affect the activity of Na(+)/K(+)-ATPase and be associated with mental diseases. Here, we demonstrate that FXYD6 is up-regulated in hepatocellular carcinoma (HCC) and enhances the migration and proliferation of HCC cells. Up-regulation of FXYD6 not only positively correlates with the increase of Na(+)/K(+)-ATPase but also coordinates with the activation of its downstream Src-ERK signaling pathway. More importantly, blocking FXYD6 by its functional antibody significantly inhibits the growth potential of the xenografted HCC tumors in mice, indicating that FXYD6 represents a potential therapeutic target toward HCC. Altogether, our results establish a critical role of FXYD6 in HCC progression and suggest that the therapy targeting FXYD6 can benefit the clinical treatment toward HCC patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Farmacologia
/
Movimento Celular
/
ATPase Trocadora de Sódio-Potássio
/
Carcinoma Hepatocelular
/
Ensaios Antitumorais Modelo de Xenoenxerto
/
Linhagem Celular Tumoral
/
Carga Tumoral
/
Proliferação de Células
/
Tratamento Farmacológico
/
Células HEK293
Limite:
Animais
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Protein & Cell
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS